SCYNEXIS delays initiation of new clinical studies using the IV formulation of SCY-078 at FDA’s request
March 02, 2017 16:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., March 02, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (Nasdaq:SCYX) today announced that the United States Food and Drug Administration (FDA) has informed the...
SCYNEXIS, Inc. to Participate in Upcoming Investor Conferences
January 31, 2017 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will participate in the following upcoming investor...
SCYNEXIS Announces Appointment of Industry Veteran Marion McCourt to its Board of Directors
January 26, 2017 09:05 ET
|
SCYNEXIS, Inc.
— Former Chief Operating Officer of Medivation adds broad experience in commercial, strategy, operations and business development — — SCYNEXIS to ramp up commercial preparatory and...
SCYNEXIS Achieves New Development Milestones Reinforcing the Versatility of SCY-078 in Treating Serious Fungal Infections
December 13, 2016 08:00 ET
|
SCYNEXIS, Inc.
– Regimen of intravenous (IV) formulation of SCY-078 successfully identified and characterized to support subsequent studies – – Long-term toxicology studies completed, confirming favorable...
SCYNEXIS, Inc. to Participate in the Guggenheim Securities 4th Annual Boston Healthcare Conference
December 12, 2016 11:28 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX), a pharmaceutical company developing novel anti-infectives to address unmet therapeutic...
SCYNEXIS, Inc. Reports Third Quarter 2016 Financial Results and Provides Company Update
November 07, 2016 16:30 ET
|
SCYNEXIS, Inc.
-- Positive Results From Multiple Studies Provide Clear Evidence of Clinical Antifungal Activity and Favorable Safety Profile of SCY-078 -- -- Company is Well Positioned and...
SCYNEXIS Completes Two Additional Clinical Studies Further Supporting the Favorable Safety Profile of SCY-078
October 25, 2016 09:05 ET
|
SCYNEXIS, Inc.
SCY-078 demonstrates a low potential for certain drug-drug interactions – a relevant differentiator versus the azoles, the leading antifungal class – providing an opportunity for favorable labeling ...
SCYNEXIS Announces Complete Results from Two Phase 2 Studies of Oral SCY-078 in Patients with Candida spp. Infections and Closing of a $15 Million Term Loan
October 05, 2016 16:15 ET
|
SCYNEXIS, Inc.
Study Results Confirm Overall Antifungal Activity of Oral SCY-078 in Patients with Candida InfectionsWell-Tolerated and Active Oral Dose of SCY-078 Identified for Invasive Candidiasis PatientsEvidence...
SCYNEXIS, Inc. to Present at the Ladenburg Thalmann Healthcare Conference
September 20, 2016 09:05 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Sept. 20, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the Ladenburg Thalmann Healthcare...
SCYNEXIS, Inc. to Present at Upcoming Investor Conferences
August 31, 2016 09:25 ET
|
SCYNEXIS, Inc.
JERSEY CITY, N.J., Aug. 31, 2016 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will present at the following upcoming investor...